Lumeda develops the DigiLum™ system, a medical device that enhances photodynamic therapy (PDT) for treating advanced lung and colorectal cancers by enabling precise light dosing and reducing treatment time. This technology addresses the limitations of traditional PDT, offering a safer, toxicity-free alternative to chemotherapy and radiotherapy for patients with advanced-stage malignancies.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Advanced lung and colorectal cancers, leading causes of cancer-related deaths, often require treatments like chemotherapy and radiotherapy, which can cause significant toxicities and side effects. Traditional photodynamic therapy (PDT) faces limitations in precise light dosing and treatment time, hindering its broader adoption.
Solution
Lumeda's DigiLum™ system enhances photodynamic therapy (PDT) by enabling precise light dosing and reducing treatment time for advanced lung and colorectal cancers. DigiLum™ addresses the limitations of legacy PDT, offering a safer, toxicity-free alternative to chemotherapy and radiotherapy. The system combines light activation technology with Gleolan™ (aminolevulinic acid HCL), a prodrug that preferentially accumulates in malignant tissue, resulting in more targeted PDT with minimal damage to healthy tissue. This approach promotes PDT immunogenic effects and improves response to immune checkpoint blockade, while also augmenting laparoscopic tumor resection surgery to improve detection and treatment of residual disease.
Target Audience
The primary target audience includes patients with advanced lung and colorectal cancer, as well as oncologists and surgeons seeking safer, less toxic treatment options.
Features
- DigiLum™ system for precise light dosing in PDT
- Compatibility with Gleolan™ for targeted treatment of malignant tissue
- Reduced treatment time compared to traditional PDT methods
- Potential to reduce the use of chemotherapy and radiotherapy
- Compatible with minimally invasive and robotic-assisted surgical procedures
- Clinical studies underway in partnership with Roswell Park Comprehensive Cancer Center